1. Immunotherapy and therapeutic vaccines for chronic HBV infection
- Author
-
Christoph Neumann-Haefelin, Julia Lang-Meli, and Robert Thimme
- Subjects
Hepatitis B virus ,Cirrhosis ,medicine.medical_treatment ,T cell ,Toll-Like Receptors ,virus diseases ,Immunotherapy ,CD8-Positive T-Lymphocytes ,Biology ,medicine.disease ,digestive system diseases ,Virus ,Vaccination ,Hepatitis B, Chronic ,medicine.anatomical_structure ,Virology ,Hepatocellular carcinoma ,Immunology ,medicine ,Global health ,Animals ,Humans ,Hepatitis B Vaccines ,CD8 - Abstract
Chronic hepatitis B virus (HBV) infection is a major global health burden causing severe complications like liver cirrhosis or hepatocellular carcinoma. Curative treatment options are lacking. Therefore, there is an urgent need for new therapeutic options. Immunotherapy with the goal to restore dysfunctional HBV-specific T cell immunity is an interesting new therapeutic strategy. Based on current evidence on dysfunction of the HBV-specific CD8+ T cell response in chronic HBV infection, we will review the growing field of immunotherapeutic approaches for treatment of chronic HBV infection. The review will focus on therapies targeting T cells and will cover checkpoint inhibitors, T cell engineering, Toll-like receptor agonists and therapeutic vaccination.
- Published
- 2021
- Full Text
- View/download PDF